Additionally, the 36-month beta value for SGRY is 2.73. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for SGRY is 73.18M and currently, short sellers hold a 12.92% ratio of that float. The average trading volume of SGRY on February 13, 2025 was 1.47M shares.
SGRY) stock’s latest price update
The stock price of Surgery Partners Inc (NASDAQ: SGRY) has plunged by -1.55 when compared to previous closing price of 25.75, but the company has seen a -1.71% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-01-31 that As the global private equity industry took tentative steps toward recovery in 2024, Japan raced ahead. The value of private equity investment in Japan jumped nearly 41% over the prior-year total in 2024, far outpacing the 25% year-over-year gain in global private equity deal value, according to S&P Global Market Intelligence data.
SGRY’s Market Performance
Surgery Partners Inc (SGRY) has seen a -1.71% fall in stock performance for the week, with a 19.80% gain in the past month and a -16.50% plunge in the past quarter. The volatility ratio for the week is 1.61%, and the volatility levels for the past 30 days are at 2.97% for SGRY. The simple moving average for the past 20 days is 7.63% for SGRY’s stock, with a -4.86% simple moving average for the past 200 days.
Analysts’ Opinion of SGRY
Many brokerage firms have already submitted their reports for SGRY stocks, with BofA Securities repeating the rating for SGRY by listing it as a “Buy.” The predicted price for SGRY in the upcoming period, according to BofA Securities is $30 based on the research report published on December 16, 2024 of the previous year 2024.
UBS, on the other hand, stated in their research note that they expect to see SGRY reach a price target of $38. The rating they have provided for SGRY stocks is “Buy” according to the report published on October 14th, 2024.
SGRY Trading at 14.30% from the 50-Day Moving Average
After a stumble in the market that brought SGRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.18% of loss for the given period.
Volatility was left at 2.97%, however, over the last 30 days, the volatility rate increased by 1.61%, as shares surge +27.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.29% upper at present.
During the last 5 trading sessions, SGRY fell by -1.71%, which changed the moving average for the period of 200-days by +2.05% in comparison to the 20-day moving average, which settled at $23.55. In addition, Surgery Partners Inc saw 19.74% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SGRY starting from Bane Harrison R., who sale 56,315 shares at the price of $25.64 back on Feb 07 ’25. After this action, Bane Harrison R. now owns 107,037 shares of Surgery Partners Inc, valued at $1,443,917 using the latest closing price.
Doherty David T, the Chief Financial Officer of Surgery Partners Inc, sale 13,641 shares at $25.61 during a trade that took place back on Feb 07 ’25, which means that Doherty David T is holding 108,862 shares at $349,346 based on the most recent closing price.
Stock Fundamentals for SGRY
Current profitability levels for the company are sitting at:
- 0.13 for the present operating margin
- 0.21 for the gross margin
The net margin for Surgery Partners Inc stands at -0.02. The total capital return value is set at 0.05. Equity return is now at value -3.11, with -0.85 for asset returns.
Based on Surgery Partners Inc (SGRY), the company’s capital structure generated 0.65 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at 1.86. The interest coverage ratio of the stock is 1.8.
Currently, EBITDA for the company is 446.1 million with net debt to EBITDA at 6.43. When we switch over and look at the enterprise to sales, we see a ratio of 2.18. The receivables turnover for the company is 5.5for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.80.
Conclusion
In conclusion, Surgery Partners Inc (SGRY) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
